Sign Up For Updates

Achieving Safe and Effective Moderate to Deep Neuromuscular Blockade and Reversal in the Perioperative Setting

On-demand Activity Coming Soon


In this interprofessional activity, expert faculty will use patient cases to discuss the clinical effects of neuromuscular blocking and reversal agents, including key components of NMB and reversal during the intraoperative phase of care and neuromuscular monitoring. Criteria for use, dosing of specific reversal agents and assessment of risk factors and mitigation of post-operative complications will also be discussed.


Welcome and Introductory Remarks
Rachel C. Wolfe , Pharm.D., M.H.A., BCCCP

Pharmacology of Neuromuscular Blocking and Reversal Agents and Patient Risk Factors
Rachel C. Wolfe , Pharm.D., M.H.A., BCCCP

Intraoperative Monitoring and Assessment/Monitoring of Patient Risk Factors
Glenn S. Murphy, M.D.

Addressing Post-operative Complications and Residual Blockade
Deborah Wagner, Pharm.D., FASHP

Wrap up and Questions and Answers/Panel Discussion
All Faculty

Learning Objectives
  • Assess risk for post-operative complications in patients receiving neuromuscular blocking agents (NMBA).
  • Explain the key components of neuromuscular blockade (NMB) and reversal during the intraoperative phase of care. 
  • Summarize the impact of residual NMB on patient and health care system outcomes. 
  • Apply strategies to improve interprofessional communication across the continuum of care when managing patients receiving NMB agents.
Like your favorites to provide us feedback!

Target Audience

This activity was planned to meet the educational needs of pharmacists, physicians, physician assistants, and nurse practitioners involved in care for surgical patients requiring neuromuscular blockade.


This online activity consists of slide presentations, active learning, and evaluation. View the system requirements.


Rachel Wolfe, Pharm.D.
Consultant and Speakers Bureau, Merck

Glenn Murphy, M.D.
Speakers Bureau and Advisory Board, Merck

Deborah Wagner, Pharm.D., FASHP
Advisory Board, Merck and Fresenius Kabi

All other planners, presenters, reviewers, ASHP staff, and others with an opportunity to control content report no financial relationships relevant* to this activity.

*As defined by the ACCME definition of commercial entity.

CPE Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

ACPE #: 0204‐0000‐20‐436‐H01‐P
Release Date: January 20, 2021
Expiration Date: May 12, 2022
Activity Type: Application-based
CE Credits: 1.5 hours
Activity Fee: Free of Charge

CME Information

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claim CE Within 60 Days

Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.

To receive CE credit, complete the steps below within 60 days of completing the activity.

  1. View entire presentation and answer all polling questions.
  2. Click "Complete Activity" on the last slide to link to complete the assessment and evaluation.
  3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credit(s).